EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSLACG00000014158
Gene Symbol: GABRG2
4 Cross references
208 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSLACG00000004091
Gene Symbol: GABRG3
2 Cross references
293 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSLACG00000004113
Gene Symbol: GABBR1
3 Cross references
264 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSLACG00000014981
Gene Symbol: GCGR
4 Cross references
112 Possible Orthologues:

Glucokinase

Ensembl ID : ENSLACG00000012891
Gene Symbol: GCK
3 Cross references
211 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSLACG00000006120
Gene Symbol: GBA1
4 Cross references
254 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSLACG00000018465
Gene Symbol: GRIA1
4 Cross references
324 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 4

Ensembl ID : ENSLACG00000008384
Gene Symbol: GRIA4
4 Cross references
324 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSLACG00000002465
Gene Symbol: GRIN2A
4 Cross references
227 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSLACG00000008175
Gene Symbol: GRIN2B
2 Cross references
330 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSLACG00000011764
Gene Symbol: GRIN2C
4 Cross references
249 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2d

Ensembl ID : ENSLACG00000014436
Gene Symbol: GRIN2D
3 Cross references
278 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).